The synthesis and structural determination of a number of new rhodomycin derivatives,
modified in the sugar part are described. The cytotoxicity against leukemic L1210 cells of these compounds, which were isolated during the synthetic procedure.
The anthracycline quinone antibiotics doxorubicin (I, Figure 1 ) and daunomycin (II, Figure 1 ) are powerful antitumor agents and are extensively used in the chemotherapy of a wide range of human cancers.1) However, their clinical effectiveness is limited, due to a number of undesired side-effects, the most serious being the dose-related cardiotoxicity and the ability to induce multidrug resistance (MDR).2,3) On the other hand the rhodomycins, which bear structural similarities to the anthracyclines, have limited clinical applicability, due to their strong toxicities.4,5) Oxaunomycin (III, Figure 1) showed very strong cytotoxicity against murine leukemia L1210 cells, being 100-fold more active than doxorubicin and was found to possess a significant antitumor effect in some experimental tumors.6) However, it was considered too toxic for further development.
As precursors of reactive quinone methides, many natural and synthetic quinones function as bioreductive The boronate derivative (0.035mmol) was dissolved in a mixture of CH2Cl2 (3ml)/Me2CO (2ml)/AcOH (0.05 ml), and 2-methyl-2,4-pentanediol (0.1ml) was added. After being stirred for 6 hours at room temperature the reaction mixture was washed with saturated aqueous NaHCO3 and extracted with CH2Cl2. The organic layer was separated, dried over Na2SO4 and concentrated in vacuo. Compounds 17 and 18 were purified by preparative TLC (CH2Cl2/ MeOH 99/1 or 98/2). (1H, dd, J=4. 
